{"id":8575,"date":"2026-10-26T08:36:52","date_gmt":"2026-10-26T03:06:52","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/biocon-share-price-today-2026-10-26\/"},"modified":"2026-10-26T17:23:30","modified_gmt":"2026-10-26T11:53:30","slug":"biocon-share-price-today-2026-10-26","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/biocon-share-price-today-2026-10-26\/","title":{"rendered":"Biocon Limited. Share Price Today: Why BIOCON Is Rising 1.64% | 26 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: BIOCON<\/strong> \u00b7 26 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b9328.80<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+1.64%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b9329.75 \/ \u20b9321.40<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b9323.50<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>30.28 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>26 October 2026 \u00b7 03:25 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Biocon Limited shares gained 1.64% on Monday, closing at \u20b9328.80 after moving between a day&#x27;s low of \u20b9321.40 and a high of \u20b9329.75. The stock opened lower at \u20b9322.20 compared to its previous close of \u20b9323.50.<\/li>\n<li>Biocon signed a license agreement with Janssen Sciences Ireland to commercialize Yesintek, its proposed biosimilar to Stelara, in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea, and Kazakhstan. This milestone builds upon prior agreements securing entry dates in the United States, Europe, the UK, Canada, and Japan. The reference brand, Stelara, recorded worldwide sales of $6.08 billion in 2025.<\/li>\n<li>Trading volume was 1.16 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Biocon Limited. share price rising on 26 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Biocon Limited shares gained 1.64% on Monday, closing at \u20b9328.80 after moving between a day&#x27;s low of \u20b9321.40 and a high of \u20b9329.75. The stock opened lower at \u20b9322.20 compared to its previous close of \u20b9323.50.<\/p>\n<p class=\"wt-copy\">The broader market and sector backdrop provided supportive conditions for the move, as the benchmark Nifty rose 0.68% while the Nifty Pharma sector index advanced 1.76%. Biocon&#x27;s session gains come against a backdrop of recent short-term weakness, having declined 5.84% over the preceding 5 trading days and 15.04% over the past 20 trading days.<\/p>\n<p class=\"wt-copy\">Company disclosures showed that Biocon announced a license agreement with Janssen Sciences Ireland on October 26, 2026, clearing the way for the commercialization of Yesintek, its proposed biosimilar to Stelara, across multiple global markets including Australia, Brazil, China, and South Korea. This follows earlier announcements regarding global patent settlements and market entries, though broader market participation and sector strength also provided context for today&#x27;s session.<\/p>\n<p class=\"wt-copy\">30.28 lakh shares traded by 26 October 2026 \u00b7 03:25 PM IST. This compares with a 20-day average daily volume of 26.13 lakh shares (1.16 times). The five-day average daily volume was 26.32 lakh shares. Separately, the NSE report for 23 October 2026 showed 18.25 lakh shares delivered, representing 52.58% of that day\u2019s traded volume. The same report recorded 51,014 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Sector strength and recent corporate announcements<\/strong><\/p>\n<p class=\"wt-copy\">Biocon shares rose 1.64% alongside strong performance in the broader pharmaceutical sector and following the announcement of international commercialization rights for its biosimilar portfolio. The move reflects positive sentiment in line with industry trends, coupled with stable cash trading volumes.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Biosimilar Stelara Market Entry in Additional Global Regions<\/div>\n<div class=\"wt-card-date\">26 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Biocon signed a license agreement with Janssen Sciences Ireland to commercialize Yesintek, its proposed biosimilar to Stelara, in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea, and Kazakhstan. This milestone builds upon prior agreements securing entry dates in the United States, Europe, the UK, Canada, and Japan. The reference brand, Stelara, recorded worldwide sales of $6.08 billion in 2025.<\/p>\n<p class=\"wt-copy\">Expanding commercialization rights across major international markets strengthens Biocon&#x27;s global biosimilars footprint and long-term revenue potential in the autoimmune disease segment.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/BIOCON_26102026082555_CompanyStatement.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Global Patent Settlement for Pebrilzo<\/div>\n<div class=\"wt-card-date\">14 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Biocon entered into a global settlement and license agreement with Genentech to resolve pending disputes and secure earliest licensed launch dates for Pebrilzo, a biosimilar to Perjeta. The agreement permits launches in the European Union and UK in the first quarter of calendar year 2027, the U.S. in the third quarter of calendar year 2028, and across various Rest of the World markets between calendar year 2026 and 2028.<\/p>\n<p class=\"wt-copy\">Resolving litigation and locking in defined launch timelines removes regulatory uncertainty and provides clear visibility for the company&#x27;s oncology biosimilars pipeline.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/BIOCON_14102026082951_SEIntimation.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Order \/ business win<\/div>\n<div class=\"wt-card-date\">8 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated September 08, 2026, titled &quot;Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/BIOCON_08092026083042_Pressrelease08092026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Business update<\/div>\n<div class=\"wt-card-date\">21 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated September 21, 2026, titled &quot;Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/BIOCON_21092026082614_Pressrelease21092026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholder-return \/ corporate action<\/div>\n<div class=\"wt-card-date\">9 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Communication regarding remittance of final dividend for the FY 2025-26.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/BIOCON_09092026135825_SE_Intimation.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">44.68%<\/div>\n<div class=\"wt-note\">44.68% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">8.64%<\/div>\n<div class=\"wt-note\">8.14% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">37.94%<\/div>\n<div class=\"wt-note\">31.52% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1743438_21102026070347_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 22.08% on 30 September 2026. This compares with 15.47% on 30 June 2026, a change of +6.61 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 40 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">SBI ESG EXCLUSIONARY STRATEGY FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">14.96 crore shares \u00b7 9.18%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">ICICI PRUDENTIAL RETIREMENT FUND-PURE EQUITY PLAN<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">6.63 crore shares \u00b7 4.07%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">KOTAK LARGE &amp; MIDCAP FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">4.20 crore shares \u00b7 2.57%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1743438_21102026070347_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">ICICI PRUDENTIAL MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">9 September 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 74.03 lakh shares \u00b7 \u20b9385.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">ACTIV PINE LLP<\/div>\n<div class=\"wt-card-date\">9 September 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 74.03 lakh shares \u00b7 \u20b9385.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">ACTIV PINE LLP<\/div>\n<div class=\"wt-card-date\">9 September 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 14.24 lakh shares \u00b7 \u20b9385.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">SBI MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">9 September 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 14.24 lakh shares \u00b7 \u20b9385.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution progress and regulatory timelines for the commercialization of Yesintek across newly licensed international markets.<\/li>\n<li>Updates regarding the planned rollout and patent settlement milestones for Pebrilzo in key regulated geographies.<\/li>\n<li>Delivery volume trends and cash market participation relative to the 20-day average volume of 3,028,217 shares.<\/li>\n<li>Performance of the Nifty Pharma sector index and broader market breadth following recent volatility.<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/biocon-share-price-today-2026-10-23\/\">Biocon Limited. Share Price Today: Why BIOCON Is Falling 2.06% | 23 October 2026 \u2014 23 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/biocon-share-price-today-2026-10-15\/\">Biocon in Focus After Global Patent Settlement for Pebrilzo | 15 October 2026 \u2014 15 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/biocon-share-price-today-2026-10-14\/\">Biocon Limited. Share Price Today: Why BIOCON Is Rising 0.82% | 14 October 2026 \u2014 14 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/biocon\/\">More Biocon Limited. news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Biocon Limited. company news?<\/h3>\n<p class=\"wt-copy\">Biocon signed a license agreement with Janssen Sciences Ireland to commercialize Yesintek, its proposed biosimilar to Stelara, in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea, and Kazakhstan. This milestone builds upon prior agreements securing entry dates in the United States, Europe, the UK, Canada, and Japan. The reference brand, Stelara, recorded worldwide sales of $6.08 billion in 2025.<\/p>\n<h3>How strong was Biocon Limited.\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">30.28 lakh shares traded, 1.16 times the 20-day average daily volume. The price and volume data are dated 26 October 2026 \u00b7 03:25 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/biocon-share-price-today-2026-10-26\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/biocon-share-price-today-2026-10-26\/\"}, \"headline\": \"Biocon Limited. Share Price Today: Why BIOCON Is Rising 1.64% | 26 October 2026\", \"description\": \"Biocon Limited. share price rose 1.64% to \u20b9328.80 today. See why BIOCON is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-26T03:06:52Z\", \"dateModified\": \"2026-10-26T17:23:22.792932+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Biocon Limited.\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"BIOCON\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/biocon-company-news-2026-10-26.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Updates\",\"summary\":\"'Company Statement'.\",\"source\":\"NSE\",\"published\":\"26-Oct-2026 08:26:50\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/BIOCON_26102026082555_CompanyStatement.pdf\",\"disclosure_text\":\"Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 E: co.secretary@biocon.com www.biocon.com BIO\/SECL\/TG\/2026-27\/75 October 26, 2026 To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai \u2013 400 001 To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai \u2013 400 051 Scrip Code - 532523 Scrip Symbol - BIOCON Subject: Company Statement Dear Sir\/Madam, Please find enclosed Company Statement w.r.t. \u201cBiocon Secures Market Entry for Yesintek\u2122, a Proposed Biosimilar to Stelara\u00ae, in Additional Global Markets\u201d. The above information will also be available on the website of the Company at www.biocon.com. Kindly take the same on record and acknowledge. Thanking You, Yours faithfully, For Biocon Limited _______________ Rajesh U. Shanoy Company Secretary and Compliance Officer M. No.: ACS 16328 Encl: Company Statement NOTIFICATION TO STOCK EXCHANGE COMPANY STATEMENT Biocon Secures Market Entry for Yesintek\u2122, a Proposed Biosimilar to Stelara\u00ae, in Additional Global Markets Bengaluru, Karnataka, India, October 26, 2026 Biocon Limited (BSE code: 532523, NSE: BIOCON) has signed a license agreement with Janssen Sciences Ireland clearing the way for the commercialization of Yesintek\u2122, its proposed biosimilar to Stelara\u00ae (Ustekinumab), in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan with immediate effect. This milestone builds on the Company\u2019s previously announced agreements with Janssen that secured market entry dates for Yesintek \u2122 in the United States, and in Europe, the UK, Canada and Japan. These additional market entry rights for biosimilar Ustekinumab will allow Biocon to offer an affordable and effective treatment option for patients impacted by autoimmune diseases in these markets. Yesintek\u2122 is a human interleukin-12 and -23 antagonist that disrupts IL-12 and IL-23 mediated signalling in immune mediated diseases and has been approved for the treatment of Crohn\u2019s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. The reference brand, Stelara\u00ae, had worldwide sales of $6.08 billion in 2025^. ^Johnson & Johnson Reported 2025 Sales Note: \u2022 All trademarks, registered or unregistered, are the property of their respective owners. \u2022 Product launches in all the countries \/ regions are subject to regulatory approval. Forward-Looking Statement: Statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update these statements except as required by law.\"},{\"summary\":\"a press release dated September 08, 2026, titled \\\"Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil\\\".\",\"category\":\"Press Release\",\"date\":\"08-Sep-2026 08:31:17\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/BIOCON_08092026083042_Pressrelease08092026.pdf\",\"headline\":\"Order \/ business win\",\"impact\":\"A material order can improve revenue visibility and capacity utilisation. The eventual earnings impact depends on execution timelines and project margins.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"a press release dated September 21, 2026, titled \\\"Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach\\\".\",\"category\":\"Press Release\",\"date\":\"21-Sep-2026 08:26:47\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/BIOCON_21092026082614_Pressrelease21092026.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4},{\"summary\":\"Communication regarding remittance of final dividend for the FY 2025-26.\",\"category\":\"General Updates\",\"date\":\"09-Sep-2026 13:58:54\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/BIOCON_09092026135825_SE_Intimation.pdf\",\"headline\":\"Shareholder-return \/ corporate action\",\"impact\":\"This affects shareholder returns or the share structure and can influence near-term investor interest.\",\"importance_score\":3,\"completeness_score\":3},{\"summary\":\"\\\"Communication regarding remittance of final dividend for the FY 2025-26\\\".\",\"category\":\"General Updates\",\"date\":\"28-Aug-2026 20:59:42\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/BIOCON_28082026205918_SE_Intimation.pdf\",\"headline\":\"Shareholder-return \/ corporate action\",\"impact\":\"This affects shareholder returns or the share structure and can influence near-term investor interest.\",\"importance_score\":3,\"completeness_score\":3}],\"recent_news\":[{\"summary\":\"a press release dated September 08, 2026, titled \\\"Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil\\\".\",\"category\":\"Press Release\",\"date\":\"08-Sep-2026 08:31:17\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/BIOCON_08092026083042_Pressrelease08092026.pdf\",\"headline\":\"Order \/ business win\",\"impact\":\"A material order can improve revenue visibility and capacity utilisation. The eventual earnings impact depends on execution timelines and project margins.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"a press release dated September 21, 2026, titled \\\"Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach\\\".\",\"category\":\"Press Release\",\"date\":\"21-Sep-2026 08:26:47\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/BIOCON_21092026082614_Pressrelease21092026.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4},{\"summary\":\"Communication regarding remittance of final dividend for the FY 2025-26.\",\"category\":\"General Updates\",\"date\":\"09-Sep-2026 13:58:54\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/BIOCON_09092026135825_SE_Intimation.pdf\",\"headline\":\"Shareholder-return \/ corporate action\",\"impact\":\"This affects shareholder returns or the share structure and can influence near-term investor interest.\",\"importance_score\":3,\"completeness_score\":3},{\"summary\":\"\\\"Communication regarding remittance of final dividend for the FY 2025-26\\\".\",\"category\":\"General Updates\",\"date\":\"28-Aug-2026 20:59:42\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/BIOCON_28082026205918_SE_Intimation.pdf\",\"headline\":\"Shareholder-return \/ corporate action\",\"impact\":\"This affects shareholder returns or the share structure and can influence near-term investor interest.\",\"importance_score\":3,\"completeness_score\":3}],\"shareholding_snapshot\":{\"promoter_pct\":44.68,\"public_pct\":55.14,\"fii_pct\":8.64,\"dii_pct\":29.3,\"mf_pct\":22.08,\"institutional_pct\":37.94,\"noninst_pct\":17.2,\"mf_scheme_count\":40,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"SBI ESG EXCLUSIONARY STRATEGY FUND\",\"shares\":149620830,\"pct\":9.18},{\"name\":\"ICICI PRUDENTIAL RETIREMENT FUND-PURE EQUITY PLAN\",\"shares\":66299307,\"pct\":4.07},{\"name\":\"KOTAK LARGE &amp; MIDCAP FUND\",\"shares\":41958298,\"pct\":2.57},{\"name\":\"HDFC MUTUAL FUND - HDFC DIVIDEND YIELD FUND\",\"shares\":17361624,\"pct\":1.07}],\"period\":\"30-SEP-2026\",\"submission_date\":\"21-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1743438_21102026070347_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":44.68,\"previous_fii_pct\":8.14,\"previous_dii_pct\":23.38,\"previous_mf_pct\":15.47,\"previous_institutional_pct\":31.52,\"previous_mf_scheme_count\":39,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"09 Sep, 2026\",\"party\":\"ICICI PRUDENTIAL MUTUAL FUND\",\"side\":\"Buy\",\"quantity\":\"74,03,166\",\"price\":\"385\",\"value\":\"\u20b9285.02 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"09 Sep, 2026\",\"party\":\"ACTIV PINE LLP\",\"side\":\"Sell\",\"quantity\":\"74,03,166\",\"price\":\"385\",\"value\":\"\u20b9285.02 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"09 Sep, 2026\",\"party\":\"ACTIV PINE LLP\",\"side\":\"Sell\",\"quantity\":\"14,23,998\",\"price\":\"385\",\"value\":\"\u20b954.82 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"09 Sep, 2026\",\"party\":\"SBI MUTUAL FUND\",\"side\":\"Buy\",\"quantity\":\"14,23,998\",\"price\":\"385\",\"value\":\"\u20b954.82 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"09 Sep, 2026\",\"party\":\"KOTAK MAHINDRA MATUAL FUND\",\"side\":\"Buy\",\"quantity\":\"12,77,000\",\"price\":\"385\",\"value\":\"\u20b949.16 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"09 Sep, 2026\",\"party\":\"ACTIV PINE LLP\",\"side\":\"Sell\",\"quantity\":\"12,77,000\",\"price\":\"385\",\"value\":\"\u20b949.16 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"09 Sep, 2026\",\"party\":\"Aditya Birla Sun Life Mutual Fund\",\"side\":\"Buy\",\"quantity\":\"1277000\",\"price\":\"385\",\"source\":\"Public market-data page\",\"value\":\"\u20b949.16 Cr\"},{\"deal_type\":\"Block\",\"date\":\"09 Sep, 2026\",\"party\":\"Whiteoak Capital Mutual Fund\",\"side\":\"Buy\",\"quantity\":\"650002\",\"price\":\"385\",\"source\":\"Public market-data page\",\"value\":\"\u20b925.03 Cr\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biocon Limited. share price rose 1.64% to \u20b9328.80 today. See why BIOCON is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":8574,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Biocon Limited. Share Price Today: Why BIOCON Is Rising 1.64% | 26 October 2026","_witty_meta_description":"Biocon Limited. share price rose 1.64% to \u20b9328.80 today. See why BIOCON is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"Biocon Limited. share price today","_witty_reason_label":"Sector strength and recent corporate announcements","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[227],"class_list":["post-8575","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-biocon"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/8575","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=8575"}],"version-history":[{"count":3,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/8575\/revisions"}],"predecessor-version":[{"id":8811,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/8575\/revisions\/8811"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/8574"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=8575"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=8575"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=8575"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}